Doxazosin

Source: Wikipedia, the free encyclopedia.

Doxazosin
Clinical data
Pronunciation/dɒkˈszəsɪn/
dok-SAY-zə-sin OR
/ˌdɒksəˈzsɪn/
DOK-sə-ZOH-sin
Trade namesCardura, Carduran, others
AHFS/Drugs.comMonograph
MedlinePlusa693045
License data
Routes of
administration
By mouth
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability65%
Protein binding98%
MetabolismLiver
Elimination half-life22 hours
Identifiers
  • (RS)-2-[4-(2,3-Dihydro-1,4-benzodioxine-2-carbonyl)piperazin-1-yl]-6,7-dimethoxyquinazolin-4-amine
JSmol)
ChiralityRacemic mixture
  • O=C(N3CCN(c2nc1cc(OC)c(OC)cc1c(n2)N)CC3)C4Oc5c(OC4)cccc5
  • InChI=1S/C23H25N5O5/c1-30-18-11-14-15(12-19(18)31-2)25-23(26-21(14)24)28-9-7-27(8-10-28)22(29)20-13-32-16-5-3-4-6-17(16)33-20/h3-6,11-12,20H,7-10,13H2,1-2H3,(H2,24,25,26) checkY
  • Key:RUZYUOTYCVRMRZ-UHFFFAOYSA-N checkY
  (verify)

Doxazosin, sold under the brand names Cardura among others, is a

by mouth.[2]

Common side effects include dizziness, sleepiness, swelling, nausea, shortness of breath, and abdominal pain.

Doxazosin was patented in 1977 and came into medical use in 1988.

generic medication.[3] In 2021, it was the 195th most commonly prescribed medication in the United States, with more than 2 million prescriptions.[5][6]

A 2021 study associated doxazosin with decelerated biological aging in humans and confirmed its causal role in longevity in

Medical uses

High blood pressure

Doxazosin is usually added to other antihypertensive therapy such as

Doxazosin is generally considered to be safe, well tolerated and effective as an add-on antihypertensive drug.[9]

Like other alpha-1 receptor antagonists, it has a role in the peri-operative management of pheochromocytoma.[10]

Benign prostatic hyperplasia

Doxazosin is considered to be effective in reducing urinary symptom scores and improving peak urinary flow in men with benign prostatic hypertrophy.[11]

History

The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) study stopped its arm of the trial looking at alpha blockers, because doxazosin was less effective than a simple diuretic, and because patients on doxazosin had a 25% higher rate of cardiovascular disease and twice the rate of congestive heart failure as patients on diuretics.[12] Pfizer, aware of the results before publication, launched a marketing campaign in early 2000, and sales were largely unaffected, despite the dangers highlighted by the study.[13][14]

References

  1. ^ a b "Cardura- doxazosin mesylate tablet". DailyMed. Retrieved 18 June 2021.
  2. ^ a b c d e f "Doxazosin Mesylate Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 17 March 2019.
  3. ^ .
  4. .
  5. ^ "The Top 300 of 2021". ClinCalc. Archived from the original on 15 January 2024. Retrieved 14 January 2024.
  6. ^ "Doxazosin - Drug Usage Statistics". ClinCalc. Retrieved 14 January 2024.
  7. PMID 35822021
    .
  8. .
  9. .
  10. .
  11. .
  12. .
  13. .
  14. .